Skip to main content

Table 2 Vorinostat in combination trials

From: New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

HDACI Other agent Disease Dosage Phase Pts No Response Reference
Vorinostat capecitabine Solid tumors VOR:300–400 mg/d PO
CAP:750–1000 mg bid PO
I 28 CR: 3%
PR: 10%
SD: 64%
[33]
Vorinostat bevacizumab kidney cancer VOR:200 mg BID × 14 d PO
BEV:15 mg/kg, q21div
I 8 SD: 42% [27]
Vorinostat bexarotene CTCL VOR:300–400 mgqdPOq28d
BEX:150–300 mg/m2qdq28d
I 19 CR: 5%
PR: 15%
SD: 63%
[28]
Vorinostat tamoxifen breast cancer VOR:400 mg/d ×21d PO
T AM:20 mg/d PO
II 19 CR: 5%
PR: 15%
[32]
Vorinostat Gemcitabine
Carboplatin/Cisplatin
NSCLC VOR:300–400 mgqdPOx7d
GEM:1000–1250 mg/m2, ivd3, 10
C BP:5.0AUC, iv/CDDP:75 mg/m2, iv d3
I 12 PR: 57%
SD: 28%
[38]
Vorinostat 13-cis-retinoid acid Pediatric CNS,
solid tumors
VOR:180–230 mg/m2 po qd
13cRA: 80 mg/m2po bid
I 13 MTD: VOR 180 mg/m2/d × 4/w
13cRA: 80 mg/m2bid
[39]
Vorinostat Carboplatin Paclitaxel solid tumors VOR:400–600 mg/d PO q21d
C BP:6.0 AUC, iv
PTX:200 mg/m2, iv
I 28 PR: 44%
SD: 28%
[34]
Vorinostat bortezomib MM VOR:100–400 mg PO d4–11
VEL:1.3 mg/m2 IV d1, 4, 8 and 11
I 23 MTD: VOR 400 mg d 4–11;VEL1.3 mg/m2d1, 4, 8, 11. [25]
  1. VEL: bortezomib; CR: complete responses; PR: partial response; SD: stable disease. MTD: maximal tolerated dose;